Irbesartan and Oseltamivir treatment of COVID-19 infection.

INTERVENTION: Trade Name: Aprovel Pharmaceutical Form: Tablet Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300‐ Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tamiflu Pharmaceutical Form: Tablet INN or Proposed INN: OSELTAMIVIR CAS Number: 196618‐13‐0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75‐ Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use CONDITION: The combined treatment in this trial will be used to treat patients with Covid‐19 infection in order to prevent the patients need for further treatment in a hospital. ; MedDRA version: 23.0 Level: LLT Classification code 10084382 Term: Coronavirus disease 2019 System Organ Class: 100000004862 Therapeutic area: Diseases [C] ‐ Virus Diseases [C02] PRIMARY OUTCOME: Main Objective: To prevent progression of Covid‐19 infections in Covid possitive patient not yet admitted to hospital. The objective is, that the active treated patient will not need further treatment during stay in a hospital. Primary end point(s): Preventing patients with Covid‐19 infection treated at home in hospitalizing for this diseace. Secondary Objective: If the patients should need hospital treatment, the secondary objective is to prevent progression of the infection causing need for invasive treatment. Timepoint(s) of evaluation of this end point: 14 days SECONDARY OUTCOME: Secondary end point(s): Reduction of Covid‐19 induced symptoms and diseace duration Timepoint(s) of evaluation of this end point: 14 days INCLUSION CRITERIA: Patients age 50‐89 years and Covid‐19 positiv and home. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 40